BridgeMD
New treatment option for Chronic Obstructive Lung Disease (COLD)
Official title Reforça't: A Community, Social, and Healthcare Program for Patients With Cardiorespiratory Conditions Upon Hospital Discharge
ClinicalTrials.gov ID: NCT06897410
What this study is testing
- What it's testing
- The goal of this randomized clinical trial is to determine whether an interdisciplinary, community-based intervention can reduce 30-day hospital readmissions and improve functional outcomes in patients aged 65 or older with chronic cardiac, respiratory, or mixed conditions following hospital discharge. The main questions it aims to answer are: Can the Reforça't program reduce 30-day hospital readmission rates to 25% compared to standard care?
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 and older
You may be able to join if
- Users admitted to the Polivalent Observation Units, Internal Medicine, or Hospital at home.
- Individuals aged 65 years or older.
- Hospital admission due to decompensation of a cardiac, respiratory, or mixed condition.
- Place of residence within the health coverage area of Sant Jaume de Calella Hospital - Corporació de Salut del Maresme i la Selva.
- Willingness to participate in the study as gathered by the signing of an informed consent document
You likely can't join if
- Users institutionalized in a nursing home
- Users already enrolled in home care programs
- Users in the Advanced Chronic Care Model program with a limited life prognosis
- Users on the waiting list for organ transplantation
- Users with language barriers
- Users with a GDS (Global Deterioration Scale) score of 5 or higher
See the full eligibility criteria
- Users admitted to the Polivalent Observation Units, Internal Medicine, or Hospital at home.
- Individuals aged 65 years or older.
- Hospital admission due to decompensation of a cardiac, respiratory, or mixed condition.
- Place of residence within the health coverage area of Sant Jaume de Calella Hospital - Corporació de Salut del Maresme i la Selva.
- Willingness to participate in the study as gathered by the signing of an informed consent document
- Users institutionalized in a nursing home
- Users already enrolled in home care programs
- Users in the Advanced Chronic Care Model program with a limited life prognosis
- Users on the waiting list for organ transplantation
- Users with language barriers
- Users with a GDS (Global Deterioration Scale) score of 5 or higher
- Users who have already been included in the Reforça't program
The study team makes the final eligibility decision.
Where it's taking place
- Calella, Barcelona, Spain
Compensation & support
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Calella, Barcelona, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.